Developer docs
API playgroundTry for free, no card

Search company profiles

MicroOptx

Full company profile

uuid0003hdr

Namestring
MicroOptx
Websiteurl
microoptx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

MicroOptx is a privately held, early-stage medical device company founded in 2014 and headquartered in Maple Grove, Minnesota. The company positions itself as a translator of academic bioengineering research into medical device products, and its naming convention (the "Micro" prefix combined with "optx") implies work on micro-scale optical or implant technology, most likely targeted at ophthalmic indications. Operating with 11-50 employees, the company's disclosed leadership consists of a Chief Scientific Officer and co-founder (Roy Martin) and a VP of Clinical Affairs (Amy Derosier), an organizational shape consistent with a clinical-stage posture rather than commercial sales. The public web presence is minimal: the corporate website currently serves only an Apache-style directory listing (cgi-bin, Google site verification files, an "our-team/" subdirectory, and a sitemap) with no substantive product, pipeline, indication, or company narrative content, which either reflects very limited commercial activity or a deliberate low public profile.

The company has no disclosed products, no pricing model, no distribution channels, no named customers, no customer segmentation, and no revenue mechanics in the available data. No certifications, regulatory milestones (e.g., FDA 510(k) clearance or PMA approval), patents, trademarks, partnerships, or M&A activity are referenced. Marketing and distribution channels are explicitly noted as unavailable in the input, reinforcing the reading that MicroOptx is operating in a pre-commercial development phase rather than a go-to-market phase.

Capital-wise, MicroOptx has raised approximately $19.2 million across three disclosed funding events between 2015 and 2019, including a $2.4 million round in June 2015, a $13.8 million round in June 2019, and a $3 million round in August 2019 with HBM Healthcare Investments disclosed as an investor. The most recent capital event dates to mid-2019, and no post-2019 financing, operational milestones, or leadership additions appear in any source block. As a result, current operating momentum, pipeline progression, and commercial readiness cannot be confirmed from the available evidence.

Short descriptiontext

MicroOptx is an early-stage, privately held medical device company founded in 2014 in Maple Grove, Minnesota that leverages academic bioengineering to develop micro-scale optical technology, most likely for ophthalmic applications, and is staffed for clinical-stage development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMaple Grove, United States
HQ citystring
Maple Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical device development, bioengineering technology, ophthalmic devices, clinical stage devices, academic bioengineering
Industry2 codes
PRIMARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Optical Instruments & Lenses3827
Product category
Medical Devices
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MicroOptx is an early-stage medical device company that leverages academic bioengineering to develop its products. Specific product features, clinical indications, and target applications are not described in the available source data. The company operates with a small team (11–50 employees) and is privately held and venture funded.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Glaukos is the pioneer and market leader in micro-invasive glaucoma surgery (MIGS) with its iStent platform. It is the most directly comparable commercial-stage peer for a company developing micro-optical or micro-scale glaucoma implants targeting the same ophthalmic surgeons and indications.

TypeEmerging player
Description

Ocular Therapeutix is a clinical-to-commercial-stage ophthalmic company developing sustained-release drug delivery and device-based therapies for glaucoma and other eye diseases. Its emerging status and overlap in glaucoma innovation make it a relevant emerging-player comparable for a small, micro-scale device company.

TypeBroad incumbent
Description

Bausch + Lomb is a diversified ophthalmic medical device and pharmaceutical company with significant presence in glaucoma and surgical devices. Its broad portfolio and surgeon relationships position it as a benchmark incumbent and potential strategic acquirer for micro-scale glaucoma technologies.

4Santen Pharmaceutical
TypeBroad incumbent
Description

Santen is a Japan-based global ophthalmic specialty company with a strong glaucoma franchise (and historical interest in InnFocus Microshunt). As a strategic acquirer and incumbent glaucoma player, it represents a relevant comparable and potential exit partner for a micro-optical glaucoma implant.

TypeDirect peer
Description

Sight Sciences markets the OMNI Surgical System and Trabeculo360 for micro-invasive glaucoma and canaloplasty procedures. As a growth-stage MIGS company with a direct overlap in target indication, customer (glaucoma surgeons), and minimally-invasive approach, it is a strong direct comparable.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec is a global leader in ophthalmic diagnostic and surgical devices, including optical coherence tomography and surgical microscopes. Its deep optical engineering heritage and surgical footprint make it a relevant broad incumbent for a micro-optical implant company.

TypeDirect peer
Description

iStar Medical is developing the MINIject suprachoroidal MIGS implant, a micro-scale glaucoma drainage device. Its minimally-invasive, implant-based approach targeting IOP reduction makes it a strong direct comparable to a micro-optical or micro-implant glaucoma device.

TypeBroad incumbent
Description

Alcon is the largest dedicated ophthalmic medical device company globally, with a broad surgical and vision-care portfolio including the Hydrus Microstent (acquired via Ivantis). It sets the commercial benchmark and competitive ceiling for any micro-scale glaucoma implant.

TypeBroad incumbent
Description

J&J Vision is a major ophthalmic surgery franchise with products across cataract, refractive, and glaucoma. Its scale, global distribution, and history of acquiring MIGS-adjacent technologies (e.g., SightLine) make it a relevant broad incumbent peer and potential acquirer.

TypeDirect peer
Description

Belkin Vision (operating alongside New World Medical) develops laser-based MIGS solutions (e.g., Eagle directSelective laser trabeculoplasty) for glaucoma. It competes for the same surgeon customers and same glaucoma treatment paradigm as a micro-scale implant approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MicroOptx

Medical Devicesmicrooptx.com

MicroOptx is an early-stage, privately held medical device company founded in 2014 in Maple Grove, Minnesota that leverages academic bioengineering to develop micro-scale optical technology, most likely for ophthalmic applications, and is staffed for clinical-stage development.

What MicroOptx does

MicroOptx is a privately held, early-stage medical device company founded in 2014 and headquartered in Maple Grove, Minnesota. The company positions itself as a translator of academic bioengineering research into medical device products, and its naming convention (the "Micro" prefix combined with "optx") implies work on micro-scale optical or implant technology, most likely targeted at ophthalmic indications. Operating with 11-50 employees, the company's disclosed leadership consists of a Chief Scientific Officer and co-founder (Roy Martin) and a VP of Clinical Affairs (Amy Derosier), an organizational shape consistent with a clinical-stage posture rather than commercial sales. The public web presence is minimal: the corporate website currently serves only an Apache-style directory listing (cgi-bin, Google site verification files, an "our-team/" subdirectory, and a sitemap) with no substantive product, pipeline, indication, or company narrative content, which either reflects very limited commercial activity or a deliberate low public profile.

The company has no disclosed products, no pricing model, no distribution channels, no named customers, no customer segmentation, and no revenue mechanics in the available data. No certifications, regulatory milestones (e.g., FDA 510(k) clearance or PMA approval), patents, trademarks, partnerships, or M&A activity are referenced. Marketing and distribution channels are explicitly noted as unavailable in the input, reinforcing the reading that MicroOptx is operating in a pre-commercial development phase rather than a go-to-market phase.

Capital-wise, MicroOptx has raised approximately $19.2 million across three disclosed funding events between 2015 and 2019, including a $2.4 million round in June 2015, a $13.8 million round in June 2019, and a $3 million round in August 2019 with HBM Healthcare Investments disclosed as an investor. The most recent capital event dates to mid-2019, and no post-2019 financing, operational milestones, or leadership additions appear in any source block. As a result, current operating momentum, pipeline progression, and commercial readiness cannot be confirmed from the available evidence.

MicroOptx firmographics

Firmographics
Name
MicroOptx
Website
https://microoptx.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
MicroOptx is an early-stage, privately held medical device company founded in 2014 in Maple Grove, Minnesota that leverages academic bioengineering to develop micro-scale optical technology, most likely for ophthalmic applications, and is staffed for clinical-stage development.
Ownership category
akta.pro rank

MicroOptx industry classification

Industry
Product category
Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)

Keywords

  • Medical device development
  • Bioengineering technology
  • Ophthalmic devices
  • Clinical stage devices
  • Academic bioengineering

Where MicroOptx is headquartered

Location

Headquarters

HQ city
Maple Grove
HQ country
United States
HQ region
North America

Markets served

MicroOptx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

MicroOptx product offering

Product offering

Core offering

MicroOptx is an early-stage medical device company that leverages academic bioengineering to develop its products. Specific product features, clinical indications, and target applications are not described in the available source data. The company operates with a small team (11–50 employees) and is privately held and venture funded.

Differentiator

Problem solved

Functional benefit

Companies that use MicroOptx

Customer profile

Ideal customer profiles1 record

MicroOptx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MicroOptx partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

MicroOptx competitors and assessment

Company assessment

Direct peers

  • Glaukos Corporation: Glaukos is the pioneer and market leader in micro-invasive glaucoma surgery (MIGS) with its iStent platform. It is the most directly comparable commercial-stage peer for a company developing micro-optical or micro-scale glaucoma implants targeting the same ophthalmic surgeons and indications.
  • Sight Sciences: Sight Sciences markets the OMNI Surgical System and Trabeculo360 for micro-invasive glaucoma and canaloplasty procedures. As a growth-stage MIGS company with a direct overlap in target indication, customer (glaucoma surgeons), and minimally-invasive approach, it is a strong direct comparable.
  • iStar Medical: iStar Medical is developing the MINIject suprachoroidal MIGS implant, a micro-scale glaucoma drainage device. Its minimally-invasive, implant-based approach targeting IOP reduction makes it a strong direct comparable to a micro-optical or micro-implant glaucoma device.
  • New World Medical (Belkin Vision): Belkin Vision (operating alongside New World Medical) develops laser-based MIGS solutions (e.g., Eagle directSelective laser trabeculoplasty) for glaucoma. It competes for the same surgeon customers and same glaucoma treatment paradigm as a micro-scale implant approach.

Emerging players

  • Ocular Therapeutix: Ocular Therapeutix is a clinical-to-commercial-stage ophthalmic company developing sustained-release drug delivery and device-based therapies for glaucoma and other eye diseases. Its emerging status and overlap in glaucoma innovation make it a relevant emerging-player comparable for a small, micro-scale device company.

Broad incumbents

  • Bausch + Lomb: Bausch + Lomb is a diversified ophthalmic medical device and pharmaceutical company with significant presence in glaucoma and surgical devices. Its broad portfolio and surgeon relationships position it as a benchmark incumbent and potential strategic acquirer for micro-scale glaucoma technologies.
  • Santen Pharmaceutical: Santen is a Japan-based global ophthalmic specialty company with a strong glaucoma franchise (and historical interest in InnFocus Microshunt). As a strategic acquirer and incumbent glaucoma player, it represents a relevant comparable and potential exit partner for a micro-optical glaucoma implant.
  • Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic diagnostic and surgical devices, including optical coherence tomography and surgical microscopes. Its deep optical engineering heritage and surgical footprint make it a relevant broad incumbent for a micro-optical implant company.
  • Alcon: Alcon is the largest dedicated ophthalmic medical device company globally, with a broad surgical and vision-care portfolio including the Hydrus Microstent (acquired via Ivantis). It sets the commercial benchmark and competitive ceiling for any micro-scale glaucoma implant.
  • Johnson & Johnson Vision: J&J Vision is a major ophthalmic surgery franchise with products across cataract, refractive, and glaucoma. Its scale, global distribution, and history of acquiring MIGS-adjacent technologies (e.g., SightLine) make it a relevant broad incumbent peer and potential acquirer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

MicroOptx social profiles

Digital presence

MicroOptx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MicroOptx leadership team

Management profile

Number of profiles

Profiles2 records

MicroOptx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MicroOptx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MicroOptx

What does MicroOptx do?

MicroOptx is an early-stage medical device company that leverages academic bioengineering to develop its products. Specific product features, clinical indications, and target applications are not described in the available source data. The company operates with a small team (11–50 employees) and is privately held and venture funded.

When was MicroOptx founded?

MicroOptx was founded in 2014. It employs 11 to 50 people.

Where is MicroOptx based?

MicroOptx is headquartered in Maple Grove, United States, in the North America region.

Who are MicroOptx's main competitors?

Direct peers on record are Glaukos Corporation, Sight Sciences, iStar Medical and New World Medical (Belkin Vision). Ocular Therapeutix is listed as an emerging player. Broad incumbents are Bausch + Lomb, Santen Pharmaceutical, Carl Zeiss Meditec, Alcon and Johnson & Johnson Vision.

Does MicroOptx have an API?

No public API is recorded for MicroOptx.

What industry is MicroOptx in?

MicroOptx's product category is Medical Devices. Its primary akta.pro industry code is HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling), with a secondary code of HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals